Play all audios:
ABSTRACT Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for
response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progressed (40%). Toxicity was acceptable, consisting mainly of myalgias (39%
of patients) and asthenia (21.4%). No myelotoxicity was observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern of action and
toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy. Access through your institution Buy or subscribe This is a preview of subscription content, access via your
institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per year only $10.79 per issue Learn more Buy this
article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in
* Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS PHASE 2 STUDY OF CABAZITAXEL AS SECOND-LINE TREATMENT IN PATIENTS
WITH HER2-NEGATIVE METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TAXANES—A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) TRIAL Article Open access 03 June 2020 NEOADJUVANT STUDY OF
NIRAPARIB IN PATIENTS WITH HER2-NEGATIVE, _BRCA_-MUTATED, RESECTABLE BREAST CANCER Article Open access 04 July 2022 A PHASE 1B OPEN-LABEL STUDY OF GEDATOLISIB (PF-05212384) IN COMBINATION
WITH OTHER ANTI-TUMOUR AGENTS FOR PATIENTS WITH ADVANCED SOLID TUMOURS AND TRIPLE-NEGATIVE BREAST CANCER Article 05 November 2022 AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Divisione di
Oncologia Medica, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy P Pronzato Authors * P Pronzato View author publications You can also search for this author inPubMed Google
Scholar * D Amoroso View author publications You can also search for this author inPubMed Google Scholar * G Bertelli View author publications You can also search for this author inPubMed
Google Scholar * PF Conte View author publications You can also search for this author inPubMed Google Scholar * MP Cusimano View author publications You can also search for this author
inPubMed Google Scholar * GB Ciottoli View author publications You can also search for this author inPubMed Google Scholar * M Gulisano View author publications You can also search for this
author inPubMed Google Scholar * R Lionetto View author publications You can also search for this author inPubMed Google Scholar * R Rosso View author publications You can also search for
this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Pronzato, P., Amoroso, D., Bertelli, G. _et al._ Phase II study of
lonidamine in metastatic breast cancer. _Br J Cancer_ 59, 251–253 (1989). https://doi.org/10.1038/bjc.1989.51 Download citation * Issue Date: 01 February 1989 * DOI:
https://doi.org/10.1038/bjc.1989.51 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently
available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative